204 related articles for article (PubMed ID: 29100552)
1. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
[TBL] [Abstract][Full Text] [Related]
2. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
[TBL] [Abstract][Full Text] [Related]
3. Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.
Woo J; Kim JB; Cho T; Yoo EH; Moon BI; Kwon H; Lim W
PLoS One; 2021; 16(9):e0257298. PubMed ID: 34525121
[TBL] [Abstract][Full Text] [Related]
4. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin.
Einbond LS; Wu HA; Kashiwazaki R; He K; Roller M; Su T; Wang X; Goldsberry S
Fitoterapia; 2012 Oct; 83(7):1160-8. PubMed ID: 22828666
[TBL] [Abstract][Full Text] [Related]
5. The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2
D'Alesio C; Bellese G; Gagliani MC; Lechiara A; Dameri M; Grasselli E; Lanfrancone L; Cortese K; Castagnola P
Biol Open; 2019 Apr; 8(4):. PubMed ID: 30967373
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
7. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
8. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474.
Bapat P; Sewell DG; Boylan M; Sharma AK; Spallholz JE
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925081
[TBL] [Abstract][Full Text] [Related]
11. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
13. Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.
Cañas A; López-Sánchez LM; Peñarando J; Valverde A; Conde F; Hernández V; Fuentes E; López-Pedrera C; de la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Biochim Biophys Acta; 2016 Apr; 1862(4):601-610. PubMed ID: 26854735
[TBL] [Abstract][Full Text] [Related]
14. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
15. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
16. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
17. Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Jandial DD; Krill LS; Chen L; Wu C; Ke Y; Xie J; Hoang BH; Zi X
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335434
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
Breast Cancer Res; 2020 Oct; 22(1):105. PubMed ID: 33023655
[TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
20. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Strasser S; Maier S; Leisser C; Saiko P; Madlener S; Bader Y; Bernhaus A; Gueorguieva M; Richter S; Mader RM; Wesierska-Gadek J; Schott H; Szekeres T; Fritzer-Szekeres M; Krupitza G
Differentiation; 2006 Dec; 74(9-10):488-98. PubMed ID: 17177846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
